On the one hand, BRAFi therapy modulates the tumor microenvironment through up-regulating the expression of melanoma antigens (e.g., MART, gp100) and peritumoral CD8+ T lymphocytes and reduction of immunosuppression cytokines and Treg [60]. Here, CD8A is linked to neoplasm.